Amarin (AMRN) Competitors $19.26 -0.03 (-0.13%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. PAHC, SDGR, AUPH, AVDL, JANX, EVO, RCUS, STOK, LENZ, and SNDXShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Phibro Animal Health (PAHC), Schrodinger (SDGR), Aurinia Pharmaceuticals (AUPH), Avadel Pharmaceuticals (AVDL), Janux Therapeutics (JANX), Evotec (EVO), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Phibro Animal Health Schrodinger Aurinia Pharmaceuticals Avadel Pharmaceuticals Janux Therapeutics Evotec Arcus Biosciences Stoke Therapeutics LENZ Therapeutics Syndax Pharmaceuticals Phibro Animal Health (NASDAQ:PAHC) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Do institutionals & insiders believe in PAHC or AMRN? 99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 3.3% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, PAHC or AMRN? Phibro Animal Health has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.30B1.15$48.26M$1.1831.28Amarin$228.61M1.74-$82.18M-$3.67-5.25 Does the media prefer PAHC or AMRN? In the previous week, Amarin had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 13 mentions for Amarin and 10 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.57 beat Amarin's score of 0.45 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PAHC or AMRN more profitable? Phibro Animal Health has a net margin of 3.73% compared to Amarin's net margin of -47.22%. Phibro Animal Health's return on equity of 32.14% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health3.73% 32.14% 6.89% Amarin -47.22%-21.18%-15.00% Do analysts recommend PAHC or AMRN? Phibro Animal Health currently has a consensus price target of $28.40, indicating a potential downside of 23.05%. Amarin has a consensus price target of $12.00, indicating a potential downside of 37.68%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, research analysts clearly believe Phibro Animal Health is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.13Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Which has more risk & volatility, PAHC or AMRN? Phibro Animal Health has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. SummaryPhibro Animal Health beats Amarin on 15 of the 17 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$397.47M$3.38B$6.13B$10.61BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-5.2421.9385.8627.54Price / Sales1.74274.32540.53202.58Price / CashN/A47.1237.9261.55Price / Book0.8210.2012.986.78Net Income-$82.18M-$52.40M$3.30B$275.79M7 Day Performance15.02%6.22%4.73%2.99%1 Month Performance26.51%15.91%9.96%9.50%1 Year Performance65.99%31.98%84.61%35.97% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.5096 of 5 stars$19.26-0.1%$12.00-37.7%+62.0%$397.47M$228.61M-5.24360Trending NewsAnalyst ForecastAnalyst RevisionPAHCPhibro Animal Health4.4076 of 5 stars$37.79-1.4%$28.40-24.8%+68.6%$1.55B$1.30B32.032,475Trending NewsAnalyst RevisionSDGRSchrodinger3.2005 of 5 stars$21.29+3.4%$26.57+24.8%+21.0%$1.52B$207.54M-8.58790Analyst ForecastAUPHAurinia Pharmaceuticals3.3048 of 5 stars$11.32-0.3%$13.00+14.8%+69.1%$1.49B$235.13M26.33300Analyst ForecastAVDLAvadel Pharmaceuticals2.554 of 5 stars$14.53-3.2%$20.86+43.5%+12.2%$1.46B$169.12M-484.3370News CoverageAnalyst DowngradeAnalyst RevisionJANXJanux Therapeutics1.8119 of 5 stars$22.76-5.2%$78.31+244.1%-46.1%$1.44B$10.59M-12.6430Analyst ForecastEVOEvotec1.6079 of 5 stars$3.99-0.5%$5.40+35.3%+22.1%$1.42B$862.40M0.004,827News CoverageAnalyst ForecastRCUSArcus Biosciences1.9027 of 5 stars$14.54+8.9%$21.14+45.4%-13.8%$1.42B$258M-4.59500News CoverageAnalyst ForecastInsider TradeGap UpHigh Trading VolumeSTOKStoke Therapeutics3.2491 of 5 stars$26.81+4.9%$25.57-4.6%+148.4%$1.40B$36.56M31.54100News CoverageAnalyst ForecastInsider TradeAnalyst RevisionLENZLENZ Therapeutics0.6633 of 5 stars$46.11-5.4%$49.60+7.6%+99.1%$1.39BN/A-24.27110Positive NewsAnalyst ForecastSNDXSyndax Pharmaceuticals3.7556 of 5 stars$16.40+5.1%$39.22+139.2%-10.2%$1.34B$23.68M-4.22110Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Phibro Animal Health Alternatives Schrodinger Alternatives Aurinia Pharmaceuticals Alternatives Avadel Pharmaceuticals Alternatives Janux Therapeutics Alternatives Evotec Alternatives Arcus Biosciences Alternatives Stoke Therapeutics Alternatives LENZ Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
